Cancer letters最新文献

{"title":"Strategic radiotherapy: a new proof of concept.","authors":"Francesca De Felice, Giuseppe Minniti","doi":"10.1016/j.canlet.2025.217897","DOIUrl":"https://doi.org/10.1016/j.canlet.2025.217897","url":null,"abstract":"","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":" ","pages":"217897"},"PeriodicalIF":9.1,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer\" [Cancer Lett 609 (2025) 217352].","authors":"Loïc Steiner, Maria Eldh, Annemarijn Offens, Rosanne E Veerman, Markus Johansson, Tammer Hemdan, Hans Netterling, Ylva Huge, Abdul-Sattar Aljabery Firas, Farhood Alamdari, Oskar Lidén, Amir Sherif, Susanne Gabrielsson","doi":"10.1016/j.canlet.2025.217876","DOIUrl":"https://doi.org/10.1016/j.canlet.2025.217876","url":null,"abstract":"","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":" ","pages":"217876"},"PeriodicalIF":9.1,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the dual nature of FLASH radiotherapy: From normal tissue sparing to tumor control","authors":"Yulu Guo ,&nbsp;Sijia Hao ,&nbsp;Qiaozhen Huang ,&nbsp;Cuixia Di ,&nbsp;Lu Gan ,&nbsp;Yi Xie ,&nbsp;Qiang Li ,&nbsp;Jing Si","doi":"10.1016/j.canlet.2025.217895","DOIUrl":"10.1016/j.canlet.2025.217895","url":null,"abstract":"<div><div>FLASH radiotherapy (FLASH-RT), characterized by the delivery of ultra-high dose rate irradiation within microseconds to milliseconds, has rapidly emerged as a paradigm-shifting approach in radiation oncology. Preclinical studies have consistently demonstrated its remarkable ability to spare normal tissues while maintaining effective tumor control, challenging long-standing paradigms of radiobiology. This review comprehensively synthesizes current experimental findings from diverse in vitro and in vivo models, including zebrafish embryos, mice, <em>Drosophila melanogaster</em>, and <em>Caenorhabditis elegans</em>, emphasizing the distinct protective effects of FLASH-RT across various tissue types. Potential mechanistic hypotheses—such as radiolytic oxygen depletion, radical recombination, immune modulation, mitochondrial dynamics, and preservation of DNA integrity—are critically evaluated to illuminate the biological foundations of the FLASH effect. Furthermore, the influence of key technical parameters, including radiation modality, total dose, dose rate, and fractionation schemes, alongside biological determinants such as tissue radiosensitivity and tumor heterogeneity, is systematically analyzed. Despite the promising preclinical evidence, major challenges persist in optimizing radiation delivery protocols, unraveling the precise biological mechanisms, and translating these findings into clinical practice. As a highly anticipated and transformative therapeutic innovation, FLASH-RT holds tremendous potential to redefine the future of cancer treatment; however, its underlying mechanisms remain elusive and continue to be a focal point of intensive multidisciplinary research.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"630 ","pages":"Article 217895"},"PeriodicalIF":9.1,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics analysis of polyamine metabolism implicates NT5E/CD73 in the progression of pancreatic cancer","authors":"Enkui Zhang ,&nbsp;Xinjia Ding ,&nbsp;Jixin Zhang ,&nbsp;Weikang Liu ,&nbsp;Guangnian Liu ,&nbsp;Mingzhe Li ,&nbsp;Xinxin Liu ,&nbsp;Yingjin Wang ,&nbsp;Fusheng Zhang ,&nbsp;Baoyi Li ,&nbsp;Yu Zhu ,&nbsp;Yupeng Yan ,&nbsp;Jiayu Liu ,&nbsp;Yuxin Wang ,&nbsp;Xiaodong Tian ,&nbsp;Yongsu Ma ,&nbsp;Yinmo Yang","doi":"10.1016/j.canlet.2025.217887","DOIUrl":"10.1016/j.canlet.2025.217887","url":null,"abstract":"<div><div>Pancreatic ductal adenocarcinoma (PDAC) exhibits profound metabolic reprogramming, with polyamine metabolism emerging as a key driver of tumor progression and immune evasion. However, its comprehensive role and clinical significance in PDAC remain largely unexplored. We performed an integrative analysis using bulk transcriptomics, single-cell RNA sequencing (scRNA-seq), and functional assays to systematically characterize polyamine metabolism in PDAC. A polyamine metabolism-based prognostic model (PMscore) was developed via principal component analysis, and key regulatory genes were identified using a random forest algorithm. Functional studies in vitro and in vivo assessed the role of NT5E (CD73), a core gene involved in polyamine metabolism, in tumor biology and the tumor microenvironment (TME). Polyamine metabolism was markedly upregulated in PDAC and associated with poor prognosis. The PMscore effectively stratified patients into three prognostic subgroups and was predictive of metabolic and immune features. NT5E was identified as a critical regulator, highly expressed in epithelial and mesenchymal cells. Its knockdown impaired polyamine metabolism, reduced tumor cell proliferation and migration, and altered TME composition. Notably, CD73⁺ cancer-associated fibroblasts (CAFs) were enriched near tumor cells, suggesting their involvement in metabolic crosstalk and immunosuppression. Our study provides a comprehensive multi-omics characterization of polyamine metabolism in PDAC. NT5E serves as a key metabolic and immunoregulatory gene, representing a promising biomarker and therapeutic target. Combined inhibition of NT5E and polyamine metabolism may offer a novel strategy to suppress tumor progression and modulate the immunosuppressive TME in PDAC.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"630 ","pages":"Article 217887"},"PeriodicalIF":9.1,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic cancer cells survive in the neural niche during neoadjuvant therapy","authors":"Kaan Çifcibaşı ,&nbsp;Ruediger Goess ,&nbsp;Enkhtsetseg Munkhbaatar ,&nbsp;Ilaria Pergolini ,&nbsp;Carsten Jäger ,&nbsp;Alexander Muckenhuber ,&nbsp;Helmut Friess ,&nbsp;Güralp Onur Ceyhan ,&nbsp;Rouzanna Istvanffy ,&nbsp;Ihsan Ekin Demir ,&nbsp;Carmen Mota Reyes","doi":"10.1016/j.canlet.2025.217894","DOIUrl":"10.1016/j.canlet.2025.217894","url":null,"abstract":"","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"630 ","pages":"Article 217894"},"PeriodicalIF":9.1,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innate lymphoid cells in pancreatic ductal adenocarcinoma: Immune regulation and therapeutic implications","authors":"Tinghui Mao ,&nbsp;Wenjiao Teng ,&nbsp;Li Lin ,&nbsp;Wei Zhou","doi":"10.1016/j.canlet.2025.217890","DOIUrl":"10.1016/j.canlet.2025.217890","url":null,"abstract":"<div><div>Over the past two decades, immunotherapy has revolutionized cancer treatment by shifting our strategies to harness the body's own immune system, with the promise of inhibiting or even eliminating tumors through methods that control and enhance immune responses. Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, features an immunosuppressive tumor immune microenvironment (TIME) that serves as the core factor contributing to poor prognosis of patients. Emerging research has unveiled the dual role of innate lymphoid cells (ILCs), acting as tissue-resident innate immune hubs, in PDAC immune regulation through their dynamic plasticity, heterogeneity, and interactions with various adaptive immune cells. This review systematically summarizes the latest research advancements in the developmental plasticity of ILC subsets and their bidirectional regulatory network in PDAC, highlighting the potential value of targeting ILCs to reshape the PDAC TIME. Future research should integrate single-cell multi-omics technologies to dissect the spatiotemporal heterogeneity of ILCs, develop strategies to activate their anti-tumor activity, and explore synergistic approaches combining chimeric antigen receptor (CAR)-NK cell therapy with existing immunotherapies, providing new paradigms for transforming PDAC from an immunologically \"cold\" tumor to an immune-sensitive one.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"629 ","pages":"Article 217890"},"PeriodicalIF":9.1,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The significance of protein N-glycosylation in the pathogenesis of lung cancer and its clinical implications.","authors":"Yibo Huang, Jin Song, Jinfeng Chen, Feng Li, Yi Zhang, Jing-Hua Yang","doi":"10.1016/j.canlet.2025.217849","DOIUrl":"https://doi.org/10.1016/j.canlet.2025.217849","url":null,"abstract":"<p><p>This comprehensive review systematically elucidates the multifaceted roles of protein N-glycosylation in lung cancer pathogenesis, including its contributions to accelerated cell proliferation, enhanced metastatic potential, promotion of epithelial‒mesenchymal transition (EMT), maintenance of stem cell characteristics, facilitation of immune evasion, preservation of angiogenesis, and diminished drug sensitivity. Additionally, the potential clinical utility of aberrant N-glycosylation is examined as a novel biomarker for early diagnosis, prognostic evaluation, and treatment monitoring in lung cancer. The analysis highlights the critical involvement of N-glycosylation in chemotherapy resistance, targeted therapy, and immunotherapy, offering new perspectives for the development of innovative therapeutic strategies. Furthermore, this review highlights promising applications of antibody-enzyme engineering technology in achieving more precise lung cancer treatments, introducing new opportunities for the field. These findings provide a significant theoretical basis and experimental evidence to support progress in lung cancer research and treatment advancements.</p>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":" ","pages":"217849"},"PeriodicalIF":9.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD51 promotes gastric cancer stemness via blocking Numb-mediated Notch1 degradation","authors":"Juzheng Peng ,&nbsp;Yuehan Yin ,&nbsp;Xuan Liu ,&nbsp;Cuncan Deng ,&nbsp;Peizhu Wang ,&nbsp;Xiaojie Hu ,&nbsp;Jiefu Chen ,&nbsp;Sicheng Peng ,&nbsp;Kuan Li ,&nbsp;Li Zhong ,&nbsp;Zhijun Zhou ,&nbsp;Yulong He ,&nbsp;Jiancheng Wang","doi":"10.1016/j.canlet.2025.217886","DOIUrl":"10.1016/j.canlet.2025.217886","url":null,"abstract":"<div><div>Gastric cancer (GC) remains a lethal malignancy with poor prognosis largely due to cancer stem cell (CSC)-driven metastasis, recurrence, and chemoresistance. This study identifies CD51 (integrin αv) as a pivotal regulator of GC stemness and malignant progression. Bioinformatics analysis of TCGA data revealed significant CD51 upregulation in GC tissues, correlating with advanced tumor stage and poor survival. Functional assays demonstrated that CD51 enhances CSC properties, including tumorsphere formation, migration, invasion, and oxaliplatin resistance. Mechanistically, CD51 interacts with Numb, a negative regulator of Notch signaling, to divert Notch1 receptor trafficking from lysosomal degradation to plasma membrane recycling, thereby amplifying Notch pathway activation. Single-cell RNA sequencing and clinical validations confirmed CD51's superior correlation with stemness scores compared to canonical CSC markers. Pharmacological inhibition of CD51 using cilengitide suppressed CSC phenotypes in vitro and inhibited tumor growth in patient-derived organoids and xenograft models. These findings establish CD51 as a novel CSC biomarker and therapeutic target, offering a strategy to disrupt Notch-dependent stemness and chemoresistance in GC.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"629 ","pages":"Article 217886"},"PeriodicalIF":9.1,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and therapeutic implications of glioma-neuron interactions","authors":"Yinyan Wang ,&nbsp;Yang Wang ,&nbsp;Hongbo Bao ,&nbsp;Zihan Wang ,&nbsp;Tao Jiang","doi":"10.1016/j.canlet.2025.217884","DOIUrl":"10.1016/j.canlet.2025.217884","url":null,"abstract":"<div><div>Glioma is the most common type of primary brain tumor and is almost always fatal. The challenge to develop more effective treatments lies in its high invasiveness and solid intratumoral heterogeneity, as well as its insensitivity to traditional radiotherapy and chemotherapy. With the rise of cancer neuroscience, mounting evidence has uncovered a multi-layered and dynamically complex network of communication between glioma cells and neurons which has given us new insights into tumor progression. The nervous system is now recognized as not merely a passive victim of tumor invasion, but as an active modulator and perhaps even driver of glioma progression. In this review, we systematically summarize the interaction of glioma with neuron mechanisms, including synaptic, electrophysiological, paracrine, metabolic, and neurotransmitter-related pathways. In addition, we investigate the extent to which these interactions are associated with gliomas and reveal their potential as therapeutic targets, thereby offering a theoretical foundation and new strategies for the precision treatment of glioma. Taken together, the cross-talk between gliomas and neurons is a dynamic, multi-level, multi-pathway co-regulated network system. Further exploration of this network may promote transformation from a tumor-focused to a tumor-neuron network-based therapeutic plan and provide new prospects for precision medicine.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"629 ","pages":"Article 217884"},"PeriodicalIF":9.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An old spice with new tricks: Curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes","authors":"Sam Khan ,&nbsp;Ankur Karmokar ,&nbsp;Lynne Howells ,&nbsp;Robert G. Britton ,&nbsp;Emma Parrott ,&nbsp;Raquel Palacios-Gallego ,&nbsp;Cristina Tufarelli ,&nbsp;Hong Cai ,&nbsp;Jennifer Higgins ,&nbsp;Nicolas Sylvius ,&nbsp;Kevin West ,&nbsp;Angus McGregor ,&nbsp;David Moore ,&nbsp;Selena G. Burgess ,&nbsp;Mark W. Richards ,&nbsp;Anja Winter ,&nbsp;Zahirah Sidat ,&nbsp;Nalini Foreman ,&nbsp;Sanne T. Hoorn ,&nbsp;Louis Vermeulen ,&nbsp;Karen Brown","doi":"10.1016/j.canlet.2025.217885","DOIUrl":"10.1016/j.canlet.2025.217885","url":null,"abstract":"<div><div>The cost of cancer care globally is unsustainable and strategies to reduce the mounting burden of cancer are urgently needed. One approach is the use of preventive therapies to reduce cancer risk; dietary-derived compounds with good safety profiles represent a promising source of potential candidates but translating encouraging preclinical data to successful trials presents significant challenges. Development of curcumin, from the spice turmeric, as a preventive therapy for colorectal cancer (CRC) is hindered by poor understanding of its mechanism of action. Using patient derived xenografts and <em>ex-vivo</em> 3D-models exposed to clinically achievable curcumin concentrations, we found that it targets proliferating cancer stem-like cells (CSCs) within premalignant adenoma and early-stage cancer tissues, with broad spectrum activity across all molecular subtypes. Transcriptomics analysis revealed that curcumin pushes CSCs towards differentiation over self-renewal, thereby inhibiting tumour development. Evidence suggests these effects involve direct protein binding of curcumin to NANOG, a master regulator of CRC CSCs, and impairment of its transcriptional activity via direct interference with NANOG-DNA binding. Furthermore, curcumin decreased the proportion of proliferating CSCs, defined by NANOG/Ki67 co-expression in patient derived explants and individuals with tumours containing a small fraction of these cells had greatly improved progression-free survival compared to those in the highest quartile for expression. The use of curcumin to minimise this cellular population may yield significant benefit and its clinical evaluation is warranted. Overall, this study provides crucial mechanistic insight, identifying patient populations likely to benefit from curcumin for prevention of sporadic CRC and theragnostic biomarkers for assessing efficacy.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"629 ","pages":"Article 217885"},"PeriodicalIF":9.1,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}